BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pralsetinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pralsetinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pralsetinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Pralsetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Multiple Therapies in Biomarker-selected Participants With Resecta
 ble Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pralsetinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704658-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pralsetinib: Phase 4 readout est. (NCT07704658)
DESCRIPTION:Pralsetinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Pra
 lsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors\nE
 stimated primary completion: 30 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pralsetinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07704658
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pralsetinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Pralsetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Har
 boring Rare Mutations.\nEstimated primary completion: 1 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pralsetinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pralsetinib: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Pralsetinib\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Ther
 apy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pralsetinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418879-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pralsetinib: Phase na readout est. (NCT07418879)
DESCRIPTION:Pralsetinib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: A 
 Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of
  RET Fusion-positive NSCLC\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pralsetinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07418879
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2227@assetmemo.bio
DTSTAMP:20261121T005827Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Pralsetinib: Phase 2 readout est. (NCT04589845)
DESCRIPTION:Pralsetinib\, phase 2.\nStudy: Tumor-agnostic Precision Immuno-
 oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study\
 nEstimated primary completion: 25 September 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pralsetinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
